2025 · 1st Quarter (Jan 1 - Mar 31)
Filed by VENABLE LLP.
Open official filingSource-reported fields
Literal source text
Advancing policies and programs to improve access to care and expand treatment options for individuals living with diabetes and obesity; The Special Diabetes Program Reauthorization Act (H.R. 2550); FDA guidance on diabetes endpoints; Policy related to the use of Continuous Glucose Monitors
Literal federal measure citations: H.R. 2550
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
